Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.

T H Brannagan1, A Pradhan, T Heiman-Patterson

  • 1Department of Neurology, MCP-Hahnemann University, Philadelphia, PA, USA. THB2006@med.cornell.edu

Neurology
|June 27, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and prognostic utility of diffusion kurtosis imaging in cervical spine degeneration: systematic review and meta-analysis.

Clinical radiology·2026
Same author

Outcome of Hearing Screening using Automated Auditory Brainstem Response (AABR) in Neonates Delivered through High Risk Pregnancies in Dhulikhel Hospital.

Kathmandu University medical journal (KUMJ)·2026
Same author

Reversing AV Block and Cardiogenic Shock in STEMI Care: A Case Report on Use of Fibrinolysis and Inotrope without PCI in Rural Nepal.

Kathmandu University medical journal (KUMJ)·2026
Same author

Quality of Life in Individuals with Tinnitus.

Kathmandu University medical journal (KUMJ)·2026
Same author

Diagnostic accuracy of computed tomography (CT)-based radiomics and artificial intelligence (AI) models in hepatocellular carcinoma: a systematic review and meta-analysis.

Clinical radiology·2025
Same author

The Surface-Topography Challenge: A Multi-Laboratory Benchmark Study to Advance the Characterization of Topography.

Tribology letters·2025

High-dose cyclophosphamide offers a safe and effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in patients refractory to standard therapies. This approach can lead to sustained remission and significant functional improvement for over three years.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
  • Patients refractory to conventional treatments often face progressive disability.

Purpose of the Study:

  • To evaluate the safety and efficacy of high-dose cyclophosphamide in CIDP patients resistant to standard therapies.
  • To assess the long-term outcomes of this treatment approach.

Main Methods:

  • Four CIDP patients received high-dose cyclophosphamide (200 mg/kg over 4 days).
  • Functional status, muscle strength, and nerve conduction studies were monitored.
  • Concomitant immunomodulatory medications were discontinued.

Main Results:

Related Experiment Videos

  • All patients demonstrated improvement in functional status and muscle strength.
  • Nerve conduction studies showed improvement in three out of four patients.
  • Treatment was safely administered, with sustained responses lasting over 3 years.

    • Conclusions:

    • High-dose cyclophosphamide is a safe treatment option for refractory CIDP.
    • This therapy can induce long-term remission and functional recovery in persistent CIDP cases.